J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mousa, S. A.
Right arrow Articles by Linhardt, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mousa, S. A.
Right arrow Articles by Linhardt, R. J.

PHARMACOKINETICS AND PHARMACODYNAMICS

Pharmacokinetics and Pharmacodynamics of Oral Heparin Solid Dosage Form in Healthy Human Subjects

Shaker A. Mousa, PhD, Fuming Zhang, PhD, Ahmad Aljada, PhD, Seema Chaturvedi, PhD, Majde Takieddin, MS, Haifeng Zhang, Lianli Chi, PhD, M. Cristina Castelli, PhD, Kristen Friedman, MPH, Michael M. Goldberg, MD and Robert J. Linhardt, PhD

From the Pharmaceutical Research Institute, Albany College of Pharmacy, Albany, New York (S. A. Mousa, A. Aljada, S. Chaturvedi, M. Takieddin, H. Zhang); Departments of Chemical and Biological Engineering, Chemistry, and Chemical Biology and Biology, Rensselaer Polytechnic Institute, Troy, New York (F. Zhang, H. Zhang, L. Chi, R. J. Linhardt); and Emisphere, Inc, Tarrytown, New York (E. Arbit, M. C. Castelli, K. Friedman, M. M. Goldberg).

The present investigation determined the molecular structure and the pharmacokinetic and pharmacodynamic profiles of oral unfractionated heparin containing oral absorption enhancer sodium N-[8-(2-hydroxybenzoyl) amino]caprylate, salcaprozate sodium (SNAC) and assessed the safety and tolerability of the orally dosed heparin solid dosage form versus other routes. Sixteen healthy men were included in this single-dose, 3-way crossover, randomized, open-label study. Disaccharide compositional analysis was performed using capillary high-performance liquid chromatography with electrospray ionization mass spectrometry detection. The pharmacodynamics of heparin were obtained from analysis of plasma anti-factor Xa, anti-factor IIa, activated partial thromboplastin time, and total tissue factor pathway inhibitor data. The molecular weight properties and the disaccharide composition of orally administered unfractionated heparin/SNAC and parenterally administered unfractionated heparin are identical and consistent with the starting pharmaceutical standard heparin. Furthermore, the anti-factor Xa/anti-factor IIa ratio achieved is of approximately 1:1. This is the first true pharmacokinetic study to measure the chemical compositions of heparin administered by different routes.

Key Words: Oral heparin • anticoagulants • pharmacokinetics • pharmacodynamics • solid dosage form • heparin composition

Address for correspondence: Shaker A. Mousa, Pharmaceutical Research Institute at Albany College of Pharmacy, 106 New Scotland Avenue, Albany, NY 12208; e-mail: mousas{at}acp.edu.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American College of Clinical Pharmacology